Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

News SummaryMost relevantAll newsSector newsTweets 

Merck KGaA Gives Details On Planned Efficiency Program

share with twitter share with LinkedIn share with facebook
share via e-mail
02/24/2012 | 05:51pm CET

-- Germany's Merck provides details about efficiency program.

-- Conglomerate joins a long list of drug makers revamping themselves.

-- Merck KGaA shares fall after restructuring update.

(Adds details, share details, background.)

   By Neetha Mahadevan 

Pharmaceutical and chemical company Merck KGaA (>> Merck KGaA) said Friday it launched a cost-cutting and efficiency plan in the wake of increased price pressures in the U.S. and Europe and a series of drug development setbacks.

The company said the plan could involve job cuts across all businesses and regions to reduce costs and address "unprecedented market shifts", but it didn't disclose details, saying management still needed to speak with relevant stakeholders for a mutually acceptable solution.

"Over the next two years, Merck needs to address unprecedented market shifts, increasing competition in key product areas and existing inefficiencies in its own organization to ensure the long-term success of its business model," Chief Executive Karl-Ludwig Kley said in a statement.

With its new cost-cutting drive, the German chemical and pharmaceutical company joins a long list of other drug makers who are revamping themselves in response to falling sales and profitability.

The need to cut costs is partly due to mounting pressure stemming from health care reforms in the U.S. and Europe, where governments are increasingly reluctant to reimburse expensive drugs and advocate the use of cheaper generic medicines. Companies such as AstraZeneca Plc (AZ.LN), Novartis AG (NVS), Roche Holding AG (ROG.VX), Pfizer Inc (>> Pfizer Inc.), Eli Lilly & Co (>> Eli Lilly & Co.) have all embarked on cost saving or restructuring programs to keep costs under control.

In addition to set-backs in its drug pipeline, Merck has also been hit by a slowdown in demand at its chemicals division, which led to disappointing developments in the last year and prompted it to tighten its outlook time and again.

In the second-quarter, it recorded a 6.5% drop in revenue at its chemicals division, while in the third-quarter profits fell due largely to weakness in its performance materials division.

The efficiency measures are part of Merck's comprehensive transformation program, announced last year, and comprises two phases, the company said.

In the first two years, Merck plans to set up a new leadership organization, implement efficiency measures and focus on long-term growth, while the second phase will be focused on exploiting new growth opportunities, it added.

Merck KGaA shares fell after the news and at 1545 GMT traded down 1.2% at EUR79.70, while the DAX benchmark index traded 0.6% higher.

-By Neetha Mahadevan, Dow Jones Newswires; +49 69 2972 5507; neetha.mahadevan@dowjones.com

(Sten Stovall contributed to this article.)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK KGAA
02:02p MERCK : Global Analyzer for Particle Counters Market- HCT Instruments, Honri, IQ..
03/23 MERCK : FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Ap..
03/23 PFIZER : FDA Grants Approval for BAVENCIO (avelumab), the First Immunotherapy Ap..
03/23 PFIZER : FDA Grants Approval for BAVENCIO (avelumab)
03/22 “BOLD & VIBRANT” : Merck KGaA, Darmstadt, Germany, Presents Innovati..
03/22 MERCK : unveils 2017 Darmstadt and Nairobi accelerator startups
03/21 MERCK : Introduces Mobius MyWay Portfolio for Customized Single-Use Assemblies
03/18 German shares closes flat Tuesday
03/16 MERCK : Global Trimethylgallium (TMG) Market- Akzo Nobel, SAFC Hitech, Albemarle..
03/16 MERCK : American Cancer Society Celebrates Young Scholars Joining All of Me Proj..
More news
Sector news : Specialty & Advanced Pharmaceuticals
03:42p NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03:14a YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
03/23 FDA OKs Merck KGaA and Pfizer's avelumab for rare type of skin cancer
03/23 BeiGene, Another Beijing Venture In Cancer Therapy
03/10 Pfizer And Merck Go For An Even Longer Throw Of The Javelin
03/09 Merck KGaA's (MKGAF) CEO Stefan Oschmann on Q4 2016 Results - Earnings Call T..
03/09 Merck KGaA 2016 Q4 - Results - Earnings Call Slides
Financials (€)
Sales 2017 15 592 M
EBIT 2017 3 260 M
Net income 2017 1 846 M
Debt 2017 9 565 M
Yield 2017 1,25%
P/E ratio 2017 23,69
P/E ratio 2018 20,10
EV / Sales 2017 1,46x
EV / Sales 2018 1,29x
Capitalization 13 202 M
More Financials
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 110 €
Spread / Average Target 7,9%
Consensus details
EPS Revisions
More Estimates Revisions
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA3.03%14 210
ABBVIE INC4.84%104 618
More Results